Fri, Jul 25, 2014, 1:07 AM EDT - U.S. Markets open in 8 hrs 23 mins


% | $
Click the to save as a favorite.

Trius Therapeutics, Inc. (TSRX) Message Board

vskomarovsky 7 posts  |  Last Activity: Jul 15, 2014 10:19 AM Member since: Feb 9, 2006
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    Forbes comment stream

    by themicrokid Jul 14, 2014 3:34 PM
    vskomarovsky vskomarovsky Jul 15, 2014 10:19 AM Flag

    The real enemy is DMD. The rest is pathetic. Kid, thanks for putting dots on i.

  • Reply to

    Anybody....Jonmolten, bionerd etc...

    by kgrichard5 Jul 11, 2014 10:58 AM
    vskomarovsky vskomarovsky Jul 11, 2014 11:44 AM Flag

    Promising makes him feel more important.

    Sentiment: Hold

  • Chris Garabedian - President and Chief Executive Officer
    I know I am not going to give the number, I don’t give the numbers. So but here is what I would say, we at Sarepta, who have looked at this data from day one with a critical eye have believed that there is a real effect here biochemically, clinically and we are very pleased with the safety profile. So from the beginning when we submitted that first briefing document on the 48 week data back in February of 2013 we were confident that this might warrant being looked at that for an accelerated approval, okay. We have only seen our confidence increase as we have gotten more and more updates on the clinical and safety outcome parameters. Our confidence in our dataset has increased even further now that we spend the last six months really talking to a lot of experts in the field, these are experts in natural history, they are experts in dystrophin, they are experts in pulmonary function, they are just practicing clinicians who see a lot of Duchene and the more we share our dataset with them and get their feedback, what do they think, that gives us even more confidence that our view on the dataset is the right one that this drug is working.

    So our confidence level, I would say, has increased over the time as the data has held up and I would say given the recent FDA communications, I am confident that there is more of an understanding on the FDA's part of this disease of how we conducted the study, of the expert opinions, they have talked to some of the experts directly themselves. And so I think overall, my confidence level has increased over that period, over the last year because of additional data, additional perspectives from experts.

    Sentiment: Strong Buy

  • Reply to


    by bionerd51 Apr 30, 2014 10:03 AM
    vskomarovsky vskomarovsky Apr 30, 2014 12:53 PM Flag

    Nerd, as always - your presence on this board stops shaking the boat.

    Sentiment: Strong Buy

  • Reply to

    Stop focusing all the time on the stock price

    by starfe11 Apr 27, 2014 5:07 PM
    vskomarovsky vskomarovsky Apr 27, 2014 5:12 PM Flag

    You of course are talking about your major investment - RNA.

  • Reply to

    Why did the FDA attend our walk tests?

    by bf109gee Apr 27, 2014 3:26 PM
    vskomarovsky vskomarovsky Apr 27, 2014 4:01 PM Flag

    That is a brilliant vision. Perfect cartoon.

    Sentiment: Strong Buy

  • Reply to

    got 5 minutes

    by simp08801 Apr 27, 2014 9:00 AM
    vskomarovsky vskomarovsky Apr 27, 2014 3:54 PM Flag

    "Who do you think you are?"... If he is honest - the answer should be a such: " I am a paid by pharmaceuticals callow chemist (or his wife), and I'm here to doubt the truth by all available pseudo-scientific gibberish in order to #$%$ and confuse naive investors, fooling them into selling their shares.... Also I was discharged by the Sarepta."

    Sentiment: Strong Buy

13.630.00(0.00%)Sep 11 4:00 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.